newsfilter
← Latest News
Business Wire·

enGene to Participate in Upcoming Investor Conferences

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing